Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2018

View Archived Issues

Phase I trial explores cellular adoptive immunotherapy in sarcoma

ADAMTS18 found behind alveolar dysplasia and lung morphology

Nanotech-enabled mRNA delivery reactivates tumor suppressor

Vaspin shows cardioprotective effect in myocardial ischemia/reperfusion injury animal models

Treatment with the novel GPR88 agonist RTI-13951-33 reduces alcohol intake in vivo

QCA-570 demonstrates efficacy and safety in preclinical leukemia models

National Institute of Biomedical Innovation and Biken synthesize lipid A adjuvant

Pharming receives complete response letter from FDA for Ruconest

Hadasit Medical Research Services and Development, Ramot patent glycogen synthase inhibitors

Jiangsu Hansoh Pharmaceutical Group, Shanghai Hansoh Biomedical discover MAP3K5 inhibitors

Global phase III ALPS study of roxadustat meets primary endpoints

Hulio, a biosimilar to adalimumab, receives marketing authorization in Europe

IRLAB announces updates to its pipeline

PET tracer for renal imaging tested in vivo

First patient treated in phase I trial of BAY-1905254

First patient enrolled in phase IIa HIV study of GnRH agonist ISR-048

Further studies planned after first-in-human trial of respiratory disease candidate OATD-01

FDA accepts Cardurion's IND for phase I study of CRD-733

New OTC-deficient pig model of metabolic liver disease developed

Mesoblast reports survival outcomes through day 180 in phase III study of remestemcel-L

European Commission approves Braftovi with Mektovi for advanced melanoma with BRAFV600 mutation

Galectin Therapeutics reports preliminary phase Ib data on GR-MD-02 in advanced melanoma

Plasma NfL and CSF biomarkers for the diagnosis of AD in adults with Down syndrome

Lorlatinib receives first approval in Japan

Viruses use Treacle to make host cells more hospitable

Sihuan begins phase II study of benapenem

Cyp8b1 silencing improves nonalcoholic fatty liver disease in mice by remodeling the bile acid pool

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...